Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 578784100 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
ARCH Venture Fund X, L.P.
13G
|
9.4% |
5/15/2025
Event 3/31/2025
|
||
| ARCH Venture Fund X, L.P. | 9.4% | |||
| ARCH Venture Fund X Overage, L.P. | 9.4% | |||
| ARCH Venture Partners X, L.P. | 9.4% | |||
| ARCH Venture Partners X Overage, L.P. | 9.4% | |||
| ARCH Venture Partners X, LLC | 9.4% | |||
| Keith Crandell | 9.4% | |||
| Kristina Burow | 9.4% | |||
| Steven Gillis | 9.4% | |||
| Robert Nelsen | 9.4% | |||
|
Third Rock Ventures IV, L.P.
13G/A
|
9.3% |
2/13/2026
Event 12/31/2025
|
||
| Third Rock Ventures IV, L.P. | 9.3% | |||
| Third Rock Ventures GP IV, L.P. | 9.3% | |||
| TRV GP IV, LLC | 9.3% | |||
| Third Rock Ventures V, L.P. | 2.0% | |||
| Third Rock Ventures GP V, L.P. | 2.0% | |||
| TRV GP V, LLC | 2.0% | |||
|
Deep Track Capital, LP
13G/A
|
9.0% |
8/14/2025
Event 6/30/2025
|
||
| Deep Track Capital, LP | 9.0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 9.0% | |||
| David Kroin | 9.0% | |||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
9.0% |
2/13/2026
Event 12/31/2025
|
||
| Frazier Life Sciences Public Fund, L.P. | 9.0% | |||
| FHMLSP, L.P. | 9.0% | |||
| FHMLSP, L.L.C. | 9.0% | |||
| Frazier Life Sciences X, L.P. | 0.2% | |||
| FHMLS X, L.P. | 0.2% | |||
| FHMLS X, L.L.C. | 0.2% | |||
| Frazier Life Sciences XI, L.P. | 0.3% | |||
| FHMLS XI, L.P. | 0.3% | |||
| FHMLS XI, L.L.C. | 0.3% | |||
| Frazier Life Sciences XII, L.P. | 0% | |||
| FHMLS XII, L.P. | 0% | |||
| FHMLS XII, L.L.C. | 0% | |||
| James N. Topper | 0.2% | |||
| Patrick J. Heron | 0.2% | |||
| Janus Henderson Group PLC 13G/A | 5.8% |
5/15/2026
Event 3/31/2026
|
||
| BlackRock, Inc. 13G | 5.4% |
7/29/2026
Event 6/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
|
Matrix Capital Management Company, LP
13G/A
|
3.5% |
11/13/2025
Event 9/30/2025
|
||
| Matrix Capital Management Company, LP | 3.5% | |||
| David E. Goel | 3.5% | |||
|
GV 2019, L.P.
13G/A
|
2.9% |
2/6/2026
Event 12/31/2025
|
||
| GV 2019, L.P. | 1.6% | |||
| GV 2019 GP, L.P. | 1.6% | |||
| GV 2019 GP, L.L.C. | 1.6% | |||
| GV 2023, L.P. | 1.3% | |||
| GV 2023 GP, L.P. | 1.3% | |||
| GV 2023 GP, L.L.C. | 1.3% | |||
| Alphabet Holdings LLC | 2.9% | |||
| XXVI Holdings Inc. | 2.9% | |||
| Alphabet Inc. | 2.9% | |||
|
Foresite Capital Fund IV, L.P.
13G/A
|
1.4% |
11/14/2025
Event 9/30/2025
|
||
| Foresite Capital Fund IV, L.P. | 1.2% | |||
| Foresite Capital Management IV, LLC | 1.2% | |||
| Foresite Capital Fund V, L.P. | 0.2% | |||
| Foresite Capital Management V, LLC | 0.2% | |||
| James Tananbaum | 1.4% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
0% |
8/14/2026
Event 6/30/2026
|
||
| Paradigm BioCapital Advisors LP | 0% | |||
| Paradigm BioCapital Advisors GP LLC | 0% | |||
| Senai Asefaw, M.D. | 0% | |||
| Paradigm BioCapital International Fund Ltd. | 0% | |||